Novo Nordisk lines up for May Alzheimer's trial
According to database Clinical Trials, Novo Nordisk will launch clinical trials for the company's diabetes drug semaglutide in tablet form as a possible treatment for Alzheimer's in end-May.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
When Novo Nordisk announced in December that it would commence studies with oral semaglutide for treating Alzheimer's, the firm expected that this would happen in the course of the first half-year of 2021.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk Pharmatech to open new sales office in US
For subscribers
Novo Nordisk appoints new head of drug discovery
For subscribers
